Allergy Therapeutics
↗Worthing, United Kingdom
Allergy Therapeutics Plc is a commercial biotechnology company specializing in the development, manufacture, and commercialization of therapies for the diagnosis and treatment of allergic disorders. Founded in 1998 and headquartered in Worthing, United Kingdom, the company focuses on subcutaneous and sublingual allergen-specific immunotherapy (ASIT) treatments with an aluminum-free, proprietary technology platform. The company operates internationally across multiple European markets with a manufacturing facility in Spain, providing both proprietary vaccines and diagnostics for various allergic conditions including allergic rhinitis (grass and tree pollen) and food allergies (peanut allergy). Allergy Therapeutics combines established commercial operations with a clinical-stage pipeline targeting large unmet needs in allergy immunotherapy.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:-
Industry:Pharmaceuticals
Sub-Industry:Biotechnology - Allergy Immunotherapy
SIZE & FINANCIALS
Employees:501-1000
Revenue:£55M (FY 2025)
Founded:1998
Ownership:public
Status:operating
FUNDING
Stage:Public Company
Total Raised:£55M+ (includes recent warrant exercises and equity placements)
Investors:Eiffel Investment Group, Southern Fox, ZQ Capital (SkyGem), Hayfin Capital Management
STOCK
Exchange:London Stock Exchange (AIM)
Ticker:AGY (LSE), AGYTF (OTC/NASDAQ)
Market Cap:£655.3M (as of December 2025)
PIPELINE
Stage:Phase 3 and Phase 1/2
Lead Drug Stage:Phase III (Grass MATA MPL)
Modalities:Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT), Allergen Vaccines, Virus-Like Particle (VLP) Technology
Active Trials:3
Trial Phases:Phase 1: 1 | Phase 2: 1 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Allergy Therapeutics Spain, Allergy Therapeutics Italy, HAL Allergy Group (Germany, Austria, Switzerland, Netherlands)
Key Partnerships:University of Brighton - R&D collaboration on product characterization and vaccine development, Distribution agreements across European countries
COMPETITION
Position:Niche Player - Allergy Immunotherapy Leader
Competitors:ALK-Abelló A/S, Stallergenes Greer, GlaxoSmithKline, Sanofi SA, DBV Technologies, Aimmune Therapeutics, Regeneron Pharmaceuticals, Pfizer Inc. +1 more
LEADERSHIP
Key Executives:
Manuel Llobet - Chief Executive Officer
Dr. Shaun Furlong - Chief Financial Officer
Peter - Non-Executive Chairman
Cheryl - Executive Director
Dr. Tunde Otulana - Non-Executive Director
David - Non-Executive Director
Board Members:Peter (Non-Executive Chairman), Cheryl (Executive Director), Dr. Tunde Otulana, David
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Allergy Therapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.